Sign in
CompletedNo phase

Sphenopalatine Ganglion Block with Tx360 for Trigeminal Neuralgia

Key facts

Who runs it
Aretaieio Hospital
Where
Greece1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
15 people enrolled
Started
28 Feb 2021
Ended
15 Apr 2024
Type of study
Observational
Treatments tested
  • SPG block with the use of the Tx360 device
Record updated
29 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • male or female
  • older than 18 years
  • ASA I or II
  • trigeminal neuralgia of any etiology

Who cannot take part

  • rhinitis or nasal inflammation due to medication,
  • nasal or paranasal sinus surgery (within the last 3 months)
  • nasal septum perforation,
  • dryness or irritation of the nasal mucosa, localized pain, nasal discharge, or bleeding from the nose,
  • disorders related to bleeding or coagulation,
  • presence of malignancies, including angiofibroma or other tumors of the paranasal sinuses, or granulomas,
  • anatomical abnormalities of the nasal septum,
  • significant respiratory distress,
  • persistent nasal congestion lasting more than 10 days, accompanied by high fever, discolored nasal mucosa, or facial pain and headaches,
  • nasal or skull fractures occurring within the last 3 months

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study was to investigate the effect of sphenopalatine ganglion (SPG) block bilaterally through a nasal device called Tx360 by delivering 0.3cc of lidocaine 2% for pain relief in patients with Trigeminal Neuralgia (TN).

The group in the trial

  • Fifteen patients of both sexes, older than 18 years, ASA I or II, TN of any etiology

    Patients will undergo bilateral sphenopalatine ganglion block with Tx360 nasal applicator using 0.3cc lidocaine 2% in each side, once every week, for a 6-week period.

    Treatment: SPG block with the use of the Tx360 device

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sphenopalatine Ganglion Block with Tx360 Nasal Applicator for Trigeminal Neuralgia: a Prospective Observational Study
Record updated
29 October 2024